Zhu QM, MacDonald BT, Mizoguchi T, et al. Endothelial ARHGEF26 is an angiogenic factor promoting VEGF signaling. Cardiovasc Res. 2021. Nov 26.
Klarin D, Zhu QM, Emdin CA, et al. Genetic analysis in UK Biobank links insulin resistance and transendothelial migration pathways to coronary artery disease. Nat Genet. 2017;49(9):1392-1397.
Clifton MC, Dranow DM, Leed A, et al. A maltose-binding protein fusion construct yields a robust crystallography platform for MCL1. PLoS One. 2015;10(4): e0125010.
Fang C, D’Souza B, Thompson CF, et al. Single diastereomer of a macrolactam core binds specifically to myeloid cell leukemia 1 (MCL1). ACS Med Chem Lett. 2014;5(12):1308-1312.
Alison Leed, Ph.D.
Alison Leed is a group leader of biophysics at the Center for the Development of Therapeutics (CDoT) at the Broad Institute of MIT and Harvard. She leads a cross-functional drug discovery project team as part of the Broad–Bayer Collaboration for Cardiometabolic Risk and supports the biochemistry and biophysics efforts of other CDoT project teams. She has extensive experience in protein and small molecule nuclear magnetic resonance (NMR) and additional expertise in early hit-to-lead drug discovery, fragment- and structure-based drug design, and biophysical assay development.
Prior to joining the Broad Institute in 2012, Leed completed her doctoral studies and postdoctoral training at Harvard Medical School (HMS), in the laboratory of Gerhard Wagner. At HMS, she used multi-dimensional NMR to determine protein structures and study protein-protein interactions. She also served as a consultant for Eutropics Pharmaceuticals, providing experimental NMR data to support a drug-discovery program.
Leed holds a Ph.D. in biological chemistry and molecular pharmacology from HMS and a B.S. in biochemistry, with a minor in mathematics, from Georgetown University, where she was a John Carroll Scholar.
Contact Alison Leed via email at firstname.lastname@example.org